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Abstract
Background
Little is known about publication agreements between industry and academic investigators
in trial protocols and the consistency of these agreements with corresponding statements in
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publications. We aimed to investigate (i) the existence and types of publication agreements
in trial protocols, (ii) the completeness and consistency of the reporting of these agreements
in subsequent publications, and (iii) the frequency of co-authorship by industry employees.
Methods and Findings
We used a retrospective cohort of randomized clinical trials (RCTs) based on archived pro-
tocols approved by six research ethics committees between 13 January 2000 and 25
November 2003. Only RCTs with industry involvement were eligible. We investigated the
documentation of publication agreements in RCT protocols and statements in correspond-
ing journal publications. Of 647 eligible RCT protocols, 456 (70.5%) mentioned an agree-
ment regarding publication of results. Of these 456, 393 (86.2%) documented an industry
partner’s right to disapprove or at least review proposed manuscripts; 39 (8.6%) agree-
ments were without constraints of publication. The remaining 24 (5.3%) protocols referred
to separate agreement documents not accessible to us. Of those 432 protocols with an
accessible publication agreement, 268 (62.0%) trials were published. Most agreements
documented in the protocol were not reported in the subsequent publication (197/268
[73.5%]). Of 71 agreements reported in publications, 52 (73.2%) were concordant with
those documented in the protocol. In 14 of 37 (37.8%) publications in which statements sug-
gested unrestricted publication rights, at least one co-author was an industry employee. In
25 protocol-publication pairs, author statements in publications suggested no constraints,
but 18 corresponding protocols documented restricting agreements.
Conclusions
Publication agreements constraining academic authors’ independence are common. Jour-
nal articles seldom report on publication agreements, and, if they do, statements can be dis-
crepant with the trial protocol.
Author Summary
WhyWas This Study Done?
• Many randomized trials are designed and sponsored by for-profit companies that con-
tract academic investigators to recruit and manage patients.
• Clinical research under these circumstances is a business transaction that bears the
potential for conflicts of interest, in particular with respect to trial publication.
• Besides evidence from a small sample, it was unclear how often trial protocols included
publication agreements between industry and academic investigators, whether these
agreements constrained the investigators’ publication rights, and how consistent such
agreements stated in trial protocols were with those reported in corresponding
publications.
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What Did the Researchers Do and Find?
• We investigated publication agreements in 647 randomized trial protocols approved in
2000–2003 by six research ethics committees in Switzerland, Canada, and Germany, and
in 388 corresponding journal publications.
• Seventy percent of protocols mentioned an agreement on publication rights between
industry and academic investigators; in 86% of those agreements, industry retained the
right to disapprove or at least review manuscripts before publication.
• Seventy-four percent of agreements documented in protocols were not mentioned in
corresponding journal articles.
What Do These Findings Mean?
• Publication agreements constraining academic investigators’ independence are incom-
pletely reported in publications; this may compromise the scientific evidence base estab-
lished by randomized clinical trials.
• More transparency on publication constraints is warranted.
• Half of the included journal articles were published before 2008, leaving open the possi-
bility that these findings do not reflect current reporting practice.
Introduction
Many randomized clinical trials (RCTs) are designed and sponsored by for-profit companies
[1–3]. Companies typically contract academic investigators to identify, recruit, and manage
patients. Clinical research under these circumstances is a business transaction that bears the
potential for conflicts of interest, including those regarding the publication of trial results [4].
Academic investigators’ careers depend on publication of research results in peer-reviewed
journals. For-profit companies aim for approval of new products by regulating agencies or
expansion of product indications [5]. Publication of favourable results is also part of compa-
nies’marketing strategy [6–8]. Industry-sponsored trials are less likely to be published than
those not sponsored by industry [2,3], the likelihood of publication of outcome data can be
related to the direction of the results [1,9,10], and discrepancies between trial reports submitted
to regulatory agencies and journal publications occur [11].
To promote transparency in the arrangements between industry and academia, reporting
guidelines recommend disclosure of potential conflicts of interest of authors and funders
[12,13]. Complete reporting helps readers of journal articles judge how potential conflicts of
interest may influence the reporting of trial results. Complete reporting includes details regard-
ing both (i) agreements between industry and study investigators that may affect the publica-
tion of results and (ii) co-authorship of industry employees. Several high-impact journals insist
that authors of trial reports disclose the sponsor’s role in the study [14–16]. The International
Committee of Medical Journal Editors (ICMJE) recommends that investigators should avoid
agreements with sponsors that interfere with full access to the dataset and the investigators’
ability to conduct analyses, interpret the results, and submit the manuscript for publication
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[17]. Further, it has been suggested that journal editors should review protocols or contracts
with a focus on publication rights: “Editors may choose not to consider an article if a sponsor
has asserted control over the authors’ right to publish” [18].
Previous studies have documented constraints on the publication rights of academic investi-
gators in industry-sponsored RCTs [19,20]. Gøtzsche et al. investigated such constraints in 88
RCT protocols approved by two Danish research ethics committees—44 in 1994/1995 and 44
in 2004—and subsequent journal publications. They found that industry sponsors could have
prevented publication in half of the trials. However, this study was restricted to a relatively
small sample from a single country [21].
In this article, we consider agreements on publication rights in a cohort of RCT protocols
approved by six research ethics committees (RECs) between 13 January 2000 and 25 November
2003 in three countries and the reporting of these agreements in corresponding publications.
We also investigate co-authorship by industry employees and the concordance of statements
regarding publication rights between trial protocols and corresponding publications.
Methods
Ethical Approval
The participating RECs approved the study or explicitly stated that no ethical approval was
necessary.
Aims
We aimed to investigate (i) the existence and types of publication agreements in trial protocols,
(ii) the completeness and consistency of the reporting of these agreements in subsequent publi-
cations, and (iii) the frequency of co-authorship of industry employees.
Study Design
Previous publications describe in detail the design of this retrospective cohort study [2,22]. In
brief, we examined RCT protocols approved between 13 January 2000 and 25 November 2003
by six RECs in Switzerland (Basel, Lucerne, Zurich, and Lausanne), Germany (Freiburg), and
Canada (Hamilton) (S1 Table). Of these RECs, all but one (Lucerne) were responsible for
human research in large university centres and hospitals in their respective catchment areas.
The REC in Lucerne covered an academic teaching hospital and other health research in Cen-
tral Switzerland. We used our existing contacts to establish this convenience sample of RECs.
We determined the completion status and publication history of RCTs as of 27 April 2013 by
using information available in REC files and by conducting comprehensive searches for corre-
sponding publications in databases (MEDLINE, Embase, the Cochrane Central Register of
Controlled Trials, CINAHL, the Allied and Complementary Medicine Database, Google
Scholar, and topic-specific databases) and trial registers (ClinicalTrials.gov and the WHO
International Clinical Trials Registry Platform). Two independent investigators determined
whether identified publications matched the corresponding protocol. In the case of unclear
trial completion or publication status, the REC in charge contacted the investigators using a
standardized questionnaire.
Eligibility Criteria for Protocols and Subsequent Publications
In the present analysis, we considered only RCT protocols that clearly documented industry
involvement in the design, support, or conduct of the trial (e.g., sponsorship, logistical support,
partial funding, or supply of a drug/device). We excluded protocols of studies that (i) compared
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different doses or routes of administration of the same drug (such as early dose-finding stud-
ies), (ii) enrolled only healthy volunteers, (iii) were never started, or (iv) were still ongoing as of
April 27, 2013. With respect to multiple corresponding publications, we included only the pri-
mary full publication that reported the results from the randomized comparison, and excluded
research letters, letters to the editor, and conference abstracts. In the case of more than one full
publication, we considered the first publication that included results for the RCT’s primary
outcomes.
Definitions
We defined documentation of publication rights as any statement about an agreement between
an industry sponsor and the academic investigators regarding the publication of trial results.
We classified eligible RCT protocols according to the sponsoring party (investigator or indus-
try) that assumed formal responsibility for the conduct of the trial; the sponsoring party was
identified from the following types of information in the protocol: a clearly named sponsor, a
prominently displayed company or institution logo, the affiliations of protocol authors, state-
ments about data ownership or publication rights, and statements about full funding by indus-
try or public funding agencies. Disagreements were resolved by consensus or by involving a
third investigator as arbitrator (B. K., M. B., or E. v. E.). Investigator-sponsored trials eligible
for this study had at least some industry funding, provision of study drugs, or logistical support
from industry; industry did not, however, entirely fund these trials.
Information Collected about Publication Agreements
We recorded the presence or absence of any publication agreement between the academic
investigators and industry documented in protocols and reported in publications. If reviewers
identified such documentation, they assigned it to the most appropriate of the following four
mutually exclusive categories: (i) The industry partner retains the right to disapprove any sub-
mission for publication (this included any publication using trial data [abstracts or manuscripts
for journal publications]). (ii) The industry partner retains the right to at least review and com-
ment on any manuscript/abstract before publication (further constraints may have been possi-
ble, but were not clear from the source). (iii) No constraints by the industry partner; in
particular, no right to withhold the submission from publication. (iv) Reference to a separate
publication agreement document between the industry partner and the investigator, with no
further details. Prompted by a reviewer’s comment and considering the considerable ambiguity
of original statements, we collapsed categories (i) and (ii) in the analyses herein and labelled
the combined category as follows: the industry partner retains the right to disapprove or at
least review any abstract or manuscript for publication. Examples of publication agreements in
trial protocols are provided in S2 Table.
Data Extraction Process and Search for Publications
Twelve investigators trained in clinical research methodology extracted data from the included
trial protocols and correspondence between the RECs and local investigators at the respective
centres. To increase consistency in data extraction, pairs of two reviewers extracted the initial
30% of data independently and compared results to achieve consensus; disagreements were
resolved by discussion and consultation with an arbitrator (B. K., M. B., or E. v. E.) if necessary.
If the available REC files provided no information about the publication status of a trial, we
conducted comprehensive searches of electronic databases and surveyed investigators to find
any corresponding publications as of April 27, 2013. Twenty-two investigators trained in clini-
cal research methodology extracted data from all corresponding publications, independently
Publication Agreements in Clinical Trials
PLOSMedicine | DOI:10.1371/journal.pmed.1002046 June 28, 2016 5 / 14
and in duplicate; disagreements were resolved by discussion to achieve consensus or by consul-
tation with an arbitrator (B. K., M. B., or E. v. E.). None of the reviewers among the teams
extracted data from both a protocol and its corresponding publication.
Statistical Analysis
We summarized binary data as frequencies and proportions and continuous data as medians
and interquartile ranges. Publication agreements are described for protocols and correspond-
ing publications separately. To explore differences regarding publication agreements, we strati-
fied by industry versus investigator sponsorship. Prompted by reviewer comments, we
additionally explored the differences regarding publication agreements stratified by the extent
of industry funding, categorized as (i) provision of medication/device only, (ii) partially
funded, beyond medication/device but not whole trial, and (iii) full funding of trial. When ana-
lyzing concordance between protocols and publications, we considered only those protocols in
which the publication agreement was accessible to us. We used the statistical programme R ver-
sion 3.1.2 (https://www.r-project.org/) for all analyses. Data are deposited in the Dryad Digital
Repository: doi:10.5061/dryad.3s6j7 [23].
Results
Trial Characteristics and Publications
Of 894 RCT protocols involving patients approved by the six RECs between 13 January 2000
and 25 November 2003, 247 (27.6%) had no industry involvement and were excluded. We
included 647 (72.4%) protocols, of which 456 (70.5%) mentioned publication agreements
(Fig 1). RCTs with protocols that mentioned agreements were on average larger (median sam-
ple size 360 versus 222) and more often multicentre trials (439/456 [96.3%] versus 150/191
[78.5%]). Most RCT protocols that mentioned an agreement (417/456 [91.4%]) were industry
sponsored (Table 1). In all 39 investigator-sponsored trial protocols that mentioned an agree-
ment, one or more industry partners provided drugs or logistical support. For the included 647
RCTs, we found 388 (60.0%) full journal articles (328 [60.0%] for 547 industry-sponsored
RCTs; 60 [60%] for 100 investigator-sponsored RCTs).
Types of Agreements Mentioned in Protocols and Publications
In 393 of 456 (86.2%) protocols, the industry partner had the right to disapprove or at least to
review publications proposed by academic investigators (Table 2). Publication agreements
without any constraints by the industry partner on the academic investigator were documented
in 39 (8.6%) RCT protocols (14/417 [3.4%] industry-sponsored RCTs; 25/39 [64.1%] investiga-
tor-sponsored RCTs). Twenty-four (5.3%) protocols mentioned separate agreement docu-
ments that were not accessible to us.
Of 388 full journal publications, 98 (25.3%) mentioned an agreement regarding the publica-
tion of trial results and 290 (74.7%) did not. For 61 of the 98 (62.2%) trials that mentioned an
agreement, authors reported that the industry partner had the right to disapprove or at least to
review any publication. In 37 (37.8%) publications, the author statement suggested unrestricted
publication rights (20/78 [25.6%] industry-sponsored RCTs; 17/20 [85.0%] investigator-spon-
sored RCTs) (Table 2). The distribution of RCTs with different types of publication agreements
by extent of industry funding is displayed in S3 Table.
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In 260 of 388 (67.0%) publications, at least one co-author was an industry employee (253/
328 [77.1%] industry-sponsored trials, 7/60 [11.7%] investigator-sponsored trials). The
median proportion of industry employees among all authors for journal publications was 25%
(interquartile range, 17% to 40%); it was 30% for industry-sponsored RCTs and 10% for inves-
tigator-sponsored RCTs. In 14 of the 37 (37.8%) publications in which there was a statement
that suggested unrestricted publication rights, at least one co-author was an industry employee.
Fig 1. Study flow of RCT protocols and publications. For the Zurich REC, we included RCT protocols only
from the two subsidiary RECs responsible for paediatric and surgical RCTs.
doi:10.1371/journal.pmed.1002046.g001
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Concordance between Protocols and Publications
Table 3 displays the concordance of information about publication agreements between proto-
cols and subsequent journal publications. For this analysis, we excluded 191 protocols that did
not mention a publication agreement and 24 protocols that mentioned a separate publication
agreement document that was not accessible to us. This resulted in 432 protocols; of these, 268
Table 1. Characteristics of included randomized clinical trials as extracted from trial protocols.
Characteristic No Documented Publication Policy
(n = 191)
Documented Publication Policy
(n = 456)
Total
(n = 647)
Trial sample size
Median (interquartile range) 221.5 (100, 600) 360 (160, 712.5) 318 (125,
675)
Centre status
Multicentre trial 150 (78.5%) 439 (96.3%) 589 (91.0%)
Single-centre trial 40 (20.9%) 16 (3.5%) 56 (8.7%)
Unclear 1 (0.5%) 1 (0.2%) 2 (0.3%)
Study type
Superiority trial 133 (69.6%) 334 (73.2%) 467 (72.2%)
Non-inferiority/equivalence trial 30 (15.7%) 89 (19.5%) 119 (18.4%)
Unclear 28 (14.7%) 33 (7.2%) 61 (9.4%)
Sponsorship
Industry 130 (68.1%) 417 (91.4%) 547 (84.5%)
Investigator 61 (31.9%) 39 (8.6%) 100 (15.5%)
Extent of industry funding
Fully industry funded 125 (65.4%) 401 (87.9%) 526 (81.3%)
Partially industry funded, beyond medication/
device
22 (11.5%) 22 (4.8%) 44 (6.8%)
Only medication/device funded 23 (12.0%) 21 (4.6%) 44 (6.8%)
Unclear 21 (11.0%) 12 (2.6%) 33 (5.1%)
REC
Freiburg 61 (31.9%) 134 (29.4%) 195 (30.1%)
Basel 40 (20.9%) 144 (31.6%) 184 (28.4%)
Hamilton 48 (25.1%) 68 (14.9%) 116 (17.9%)
Lausanne 30 (15.7%) 76 (16.7%) 106 (16.4%)
Lucerne 7 (3.7%) 17 (3.7%) 24 (3.7%)
Zurich 5 (2.6%) 17 (3.7%) 22 (3.4%)
General medical ﬁeld
Medical (adult) 151 (79.1%) 391 (85.7%) 542 (83.8%)
Surgical (adult) 11 (5.8%) 30 (6.6%) 41 (6.3%)
Paediatrics 29 (15.2%) 35 (7.7%) 64 (9.9%)
Five most common speciﬁc medical ﬁelds*
Oncology 20 (10.5%) 84 (18.4%) 104 (16.1%)
Cardiovascular 29 (15.2%) 55 (12.1%) 84 (13.0%)
Infectious disease 21 (11.0%) 53 (11.6%) 74 (11.4%)
Neurology 13 (6.8%) 42 (9.2%) 55 (8.5%)
Endocrinology 9 (4.7%) 40 (8.8%) 49 (7.6%)
Data are presented as frequencies (column percentages) unless stated otherwise.
*A comprehensive list of all medical ﬁelds is provided in S1 Fig.
doi:10.1371/journal.pmed.1002046.t001
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had a corresponding journal publication. In 240 of these 268 (89.6%) protocols, the industry
partner had the right to disapprove or at least review publications (Table 3). In most cases (177
of 240 [73.8%]), this agreement was not mentioned in the subsequent publication. Of all 71
journal articles that mentioned a publication agreement, 52 (73.2%) included a statement that
was in concordance with the documentation in the protocol. In 25 publications, the author
statement suggested no constraints, but for 18 of these publications, the corresponding proto-
col documented a restricting agreement (see S4 Table for excerpts from protocols and publica-
tions). In 28 (10.4%) of 268 protocols, the protocol documented that academic investigators
were free of any constraints. This was reflected in the corresponding publications in seven
instances (25.0%). In six of 268 publications (2.2%), the authors’ statement of unrestricted pub-
lication rights was in concordance with what was documented in the protocol and no industry
employee was listed as a co-author; five of these were investigator-sponsored RCTs.
Table 2. Types of publication agreements and industry employee co-authorship as documented in trial protocols and reported in journal
publications.
Publication Agreement or Industry
Co-authorship
Protocols Publications
417 Industry
Sponsored
39 Investigator
Sponsored
456 Total 78 Industry
Sponsored
20 Investigator
Sponsored
98 Total
Industry has the right to disapprove or
at least review any publication
383 (91.8%) 10 (25.6%) 393
(86.2%)
58 (74.4%) 3 (15.0%) 61 (62.2%)
No publication constraints by industry 14 (3.4%) 25 (64.1%) 39 (8.6%) 20 (25.6%) 17 (85.0%) 37 (37.8%)
Separate agreement mentioned in
protocol
20 (4.8%) 4 (10.3%) 24 (5.3%) Not applicable Not applicable Not
applicable
At least one industry employee as co-
author of publication
Not applicable Not applicable Not
applicable
65 (83.3%) 4 (20.0%) 69 (70.4%)
Data are presented as frequencies (column percentages).
We only included protocols and publications that documented/reported agreements between industry and academic investigators on publication policies;
therefore, 191 protocols (130 industry-sponsored RCTs; 61 investigator-sponsored RCTs) and 290 publications (250 industry-sponsored RCTs; 40
investigator-sponsored RCTs) were excluded.
doi:10.1371/journal.pmed.1002046.t002
Table 3. Protocols with publication agreements and the reporting of these agreements in subsequent journal publications.
Documented in Protocol Reported in Publication Total
Published*
Total with No
Publication
Found*
All
Industry Had the Right to
Disapprove or at Least
Review Any Publication
No Publication
Constraints by
Industry
Agreement Not
Reported
Industry had the right to
disapprove or at least review
any publication
45 (18.8%)$ 18 (7.5%) 177 (73.8%) 240 (61.1%) 153 (38.9%) 393
No publication constraints by
industry
1 (3.6%) 7 (25.0%)$ 20 (71.4%) 28 (71.8%) 11 (28.2%) 39
Total 46 25 197 268 164 432
We excluded 215 protocols that referred to a separate agreement document or did not mention anything about publication agreements. Data are
presented as frequencies (row percentages, with column “Total Published” in the denominator) unless stated otherwise.
*Row percentages based on denominator in column “All”.
$Concordant statements in protocol and publication.
doi:10.1371/journal.pmed.1002046.t003
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Discussion
Summary of Findings
Of 647 RCT protocols that were approved between 13 January 2000 and 25 November 2003 by
six RECs in three countries and sponsored or supported by industry, 86% documented publica-
tion constraints reserving the right of the industry partner to review the manuscript or allowing
the industry partner to disapprove the manuscript. Most agreements (74%) documented in
protocols remained unreported in subsequent publications. In 18 instances, author statements
in publications suggested no constraints by industry partners while protocols actually docu-
mented such constraints. Moreover, at least one co-author was an industry employee in two-
thirds of journal publications and in one-third of publications in which statements suggested
no publication constraints for academic authors. This suggests that, irrespective of the agree-
ment in the protocol, the industry partner could influence publication content and submission
decisions through co-authorship.
Strengths and Limitations
Our data were collected as part of a large international cohort involving six RECs that allowed
full access to trial protocols and filed correspondence between the local academic investigator
and the REC in charge [2,22]; only investigators’ brochures were exempt from assessment.
Because unrestricted access to trial protocols is necessary to maintain scientific rigor [24], we
did not ask trialists and sponsors for permission to access their protocols. Doing so could have
introduced bias because those with poor reporting practices may not have allowed additional
scrutiny. Further strengths of our study include the use of trained methodologists for data col-
lection and independent and duplicate data extraction from identified publications. Finally,
our sample included RCTs from various fields of clinical medicine, thus enhancing the gener-
alizability of our results.
Our study has limitations: First, separate agreement documents or legal contracts specifying
publication rights were not available to us. However, only 5% of protocols that mentioned pub-
lication agreements referred to such separate documents. To the extent that protocols failed to
refer to separate documents, we may have underestimated the overall prevalence of publication
agreements. Second, we did not approach the local investigators submitting protocols to the
REC to inquire whether their publication rights were actually constrained by the industry part-
ner. Therefore, we cannot estimate to what extent the documented agreements impacted the
content of publications or led to delays in publication or to non-publication of trial results.
Third, the wording of the agreements in protocols was very heterogeneous. We extracted the
original text only to provide examples but used our judgement to classify the statements
according to four prespecified categories. Because of the considerable ambiguity of the original
statements, we eventually collapsed two categories into one. Fourth, we used a convenience
sample of six RECs that were—to our knowledge—not in any way particular. Five of them had
authority for large university hospitals in their catchment areas, and one was responsible for a
large teaching hospital. We cannot say whether these RECs are representative of other RECs in
their own or other countries. Fifth, all included protocols were approved from 13 January 2000
and 25 November 2003, and half of the included publications were from the year 2007 or
before, leaving the possibility that a substantial proportion of our sample no longer reflects cur-
rent practices of reporting of publication agreements. In particular, the increasing demand for
transparency in the reporting of clinical trials through guidelines and journal policies may have
positively influenced current practice. Sixth, exploring the influence of industry co-authors in
the writing process would require additional qualitative research, for example, interviews with
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author teams; however, this was not part of the present study. Seventh, we did not collect infor-
mation regarding associated data-sharing agreements. The nature of such agreements might
have influenced the interpretation of the publication agreements that were the focus of our
study. Finally, we previously published the protocol of the overall project but not details about
the present sub-study [22]. Therefore, we kept our analysis descriptive while including our data
extraction forms detailing all collected variables in S5 Table for interested readers.
Comparison with Other Studies
Gøtzsche et al. reported that 91% of 44 protocols from industry-sponsored trials approved by
two RECs in 1994/1995 included constraints on publication rights, but none of the associated
publications reported these constraints [21]. In our larger and more recent sample, authors
provided statements about agreements on publication rights in about a quarter of journal
publications.
Based on survey data from 108 US medical schools, Schulman et al. reported that academic
institutions routinely engage in industry-sponsored research that fails to adhere to ICMJE
guidelines regarding trial design, access to data, and publication rights [20]. In another survey
focusing on institutional policies, Mello et al. approached 122 US medical schools in 2004 [19].
Of the 107 schools that participated, approximately 85% stated that they would not approve
contractual provisions giving industry sponsors the authority to revise manuscripts or decide
whether results should be published [19]. In the remaining 15%, however, the responsible office
would allow such constraints. In our sample, 86% of industry-sponsored trial protocols docu-
mented that the sponsor retained the right to disapprove or at least review any resulting publi-
cation. The key role of academic medical centres in maintaining scientific integrity has been
outlined in a policy proposal regarding their partnership with industry sponsors [25]. This pro-
posal does not, however, explicitly address the issue of publication rights.
Implications
Previous publications have documented misleading presentations of evidence, sometimes
referred to as “spin” [26]. In industry-supported trials, spin can be due to conflicts of interest
resulting from the funding arrangements [27]. Publication restrictions represent another form
of conflict of interest, as reflected in ICMJE’s recent recommendation: “Authors should avoid
entering in to agreements with study sponsors, both for-profit and non-profit, that interfere
with authors’ access to all of the study’s data or that interfere with their ability to analyze and
interpret the data and to prepare and publish manuscripts independently when and where they
choose” [17]. Publication agreements may contribute to the presentation of results in mislead-
ing ways that favour the interests of a sponsor [28]. This is clearly a possibility when a trial’s
industry sponsor has the right of disapproval, which restricts academic freedom in general.
Industry funding disclosed in trial manuscripts may represent a red flag for editors who are
to decide about acceptance. If publication restrictions are acknowledged, this may be another.
In turn, omission of such statements—or the presence of content that contradicts existing pub-
lication restrictions—deprives clinicians, guideline developers, and policy makers of such an
alert, and may be deliberate.
We acknowledge that there are instances, in which restricting the investigators’ right to pub-
lish is appropriate, e.g., separate publication of subsets of data from a multicentre trial could be
confusing. Such restrictions should, however, be limited in time, e.g., until completion of the
trial, including publication of its main results. Pending patent applications may be another jus-
tification for a time-limited delay of publication, but can certainly not excuse withholding it
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completely. We suggest that a general reference to confidentiality in the protocol without fur-
ther explanation is not sufficient to justify restriction or delay of publication.
Besides the issues of publication rights, co-authorship by industry employees on published
trial reports allows the industry editorial influence. This issue also needs consideration in the
context of possible reporting bias—in the light of our findings, journal editors should be aware
of this issue.
The cooperation between industry and academic investigators can be very fruitful and can
lead to great improvements in medical care. RECs have a crucial role in ensuring the ethical
conduct of clinical research and should therefore also consider whether commercial sponsors’
rights to disapprove publication of trial results hamper the scientific process and erode trust in
clinical research. Additionally, mandatory documentation of publication agreements in proto-
cols (as proposed recently [29]) and trial registration could improve transparency. Further
studies investigating publication agreements between academia and industry should also con-
sider contracts in addition to approved protocols.
Conclusions
Publication agreements are common in protocols of industry-sponsored RCTs. Journal publi-
cations of RCTs rarely provide readers with information about existing agreements, and when
they do, statements can be discrepant with information in the corresponding trial protocols.
Publication agreements constraining academic authors’ independence, and the incomplete
reporting of such agreements in publications, may corrupt the scientific evidence base estab-
lished by RCTs.
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